Aprea Therapeutics, Inc.: cashflow_financing
| Value | {"amount": 14688645, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"} |
|---|---|
| Period | 2024-01-01 – 2024-06-30 |
| Status | current |
| Entity | Aprea Therapeutics, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T18:02:26.698441+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/80718c11-6cfd-469a-9122-4c71364cb5e0
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001558370-24-011806Retrieved: 2026-08-19T18:02:26.698441+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001781983/cashflow-financing/2024-06-30 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/80718c11-6cfd-469a-9122-4c71364cb5e0
History
- no predecessors — first report